This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, R. H. Articles by Kwon, E. D. Search for Related Content PubMed PubMed Citation Articles by Thompson, R. H. Articles by Kwon, E. D.

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up

Departments of ¹ Urology, ² Immunology, ³ Health Sciences Research, and ⁴ Laboratory Medicine and Pathology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota and ⁵ Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida

Requests for reprints: Eugene D. Kwon, Departments of Urology and Immunology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-8371; Fax: 507-284-4987; E-mail: kwon.eugene{at}mayo.edu.

B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor. (Cancer Res 2006; 66(7): 3381-5)

This article has been cited by other articles:

				R. Karim, E. S. Jordanova, S. J. Piersma, G. G. Kenter, L. Chen, J. M. Boer, C. J. M. Melief, and S. H. van der Burg Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma Clin. Cancer Res., October 15, 2009; 15(20): 6341 - 6347. [Abstract] [Full Text] [PDF]

				R. A. Wilcox, A. L. Feldman, D. A. Wada, Z.-Z. Yang, N. I. Comfere, H. Dong, E. D. Kwon, A. J. Novak, S. N. Markovic, M. R. Pittelkow, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders Blood, September 3, 2009; 114(10): 2149 - 2158. [Abstract] [Full Text] [PDF]

				G. Chavin, Y. Sheinin, P. L. Crispen, S. A. Boorjian, T. J. Roth, L. Rangel, M. L. Blute, T. J. Sebo, D. J. Tindall, E. D. Kwon, et al. Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases Clin. Cancer Res., March 15, 2009; 15(6): 2174 - 2180. [Abstract] [Full Text] [PDF]

				B. Li, M. VanRoey, C. Wang, T.-h. T. Chen, A. Korman, and K. Jooss Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors Clin. Cancer Res., March 1, 2009; 15(5): 1623 - 1634. [Abstract] [Full Text] [PDF]

				Q. Gao, X.-Y. Wang, S.-J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B.-Z. Li, Y.-H. Shi, Y.-S. Xiao, et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 971 - 979. [Abstract] [Full Text] [PDF]

				A. Mackensen Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy ASCO Educational Book, January 1, 2009; 2009(1): 521 - 524. [Abstract] [Full Text] [PDF]

				R. H. Thompson, X. Zang, C. M. Lohse, B. C. Leibovich, S. F. Slovin, V. E. Reuter, J. C. Cheville, M. L. Blute, P. Russo, E. D. Kwon, et al. Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage Cancer Res., August 1, 2008; 68(15): 6054 - 6058. [Abstract] [Full Text] [PDF]

				S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival Clin. Cancer Res., August 1, 2008; 14(15): 4800 - 4808. [Abstract] [Full Text] [PDF]

				G. J. Freeman Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek PNAS, July 29, 2008; 105(30): 10275 - 10276. [Full Text] [PDF]

				X. Zang, R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome PNAS, December 4, 2007; 104(49): 19458 - 19463. [Abstract] [Full Text] [PDF]

				W. S. Webster, R. H. Thompson, K. J. Harris, X. Frigola, S. Kuntz, B. A. Inman, and H. Dong Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine J. Immunol., September 1, 2007; 179(5): 2860 - 2869. [Abstract] [Full Text] [PDF]

				T. J. Roth, Y. Sheinin, C. M. Lohse, S. M. Kuntz, X. Frigola, B. A. Inman, A. E. Krambeck, M. E. Mckenney, R. J. Karnes, M. L. Blute, et al. B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy Cancer Res., August 15, 2007; 67(16): 7893 - 7900. [Abstract] [Full Text] [PDF]

				M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher Jr, S. J. Yokota, and R. B. Bankert Response to Comment on "Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells" J. Immunol., July 15, 2007; 179(2): 733 - 733. [Full Text] [PDF]

				T. Okazaki and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int. Immunol., July 2, 2007; (2007) dxm057v1. [Abstract] [Full Text] [PDF]

				J. Liu, A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway Blood, July 1, 2007; 110(1): 296 - 304. [Abstract] [Full Text] [PDF]

				T. Nomi, M. Sho, T. Akahori, K. Hamada, A. Kubo, H. Kanehiro, S. Nakamura, K. Enomoto, H. Yagita, M. Azuma, et al. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2151 - 2157. [Abstract] [Full Text] [PDF]

				A. E. Krambeck, H. Dong, R. H. Thompson, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, M. L. Blute, T. J. Sebo, J. C. Cheville, A. S. Parker, et al. Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma Clin. Cancer Res., March 15, 2007; 13(6): 1749 - 1756. [Abstract] [Full Text] [PDF]

				R. H. Thompson, H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma Clin. Cancer Res., March 15, 2007; 13(6): 1757 - 1761. [Abstract] [Full Text] [PDF]

				J. Hamanishi, M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer PNAS, February 27, 2007; 104(9): 3360 - 3365. [Abstract] [Full Text] [PDF]

				G. J. Freeman, E. J. Wherry, R. Ahmed, and A. H. Sharpe Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade J. Exp. Med., October 2, 2006; 203(10): 2223 - 2227. [Abstract] [Full Text] [PDF]